
Opinion|Videos|July 29, 2024
Biosimilars in the Commercial Sector
Dr. Cannon discusses payers and PBMs making decisions about biosimilars in the commercial sector.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How are payers and PBMs making decisions about biosimilars in the commercial sector?
a. What key factors are considered for formulary decisions in the commercial sector?
b. Discussion points: What makes the commercial sector unique, employer/payer payment models.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5